Finnish biotech company LifeGlue Technologies has raised €705,000 in seed funding for its animal-free material, which companies and research groups on three continents use to grow human tissues in the lab. The Estonian Business Angels Network EstBAN was the first investor to commit to the round, at sTARTUp Day in Tartu in January 2026, where LifeGlue also won the pitch competition. Angels from Finland and Lithuania and the Finnish investor Innovestor followed.
The round started in Tartu
LifeGlue, a spin-out from Tampere University, pitched at sTARTUp Day in January 2026 and won the event’s pitch competition. EstBAN angels were the first to commit to the round, giving it the momentum that brought in the other investors.
“When we heard LifeGlue pitch in Tartu, what stood out was that they weren’t betting on a single tissue or therapy. They supply the material the whole field builds on. That made it easy to commit first. It’s also a good example of how Baltic and Nordic angels can back strong deep-tech companies together across borders,” says Heidi Kakko, business angel and member of EstBAN.
According to co-lead Martin Goroško, LifeGlue is a prime example of how collaboration among angel investors in Estonia and the wider region helps strong, science-based companies gain access to international capital and markets.
“It is gratifying to see that members of the Finnish and Lithuanian angel investor networks, FiBAN and LitBAN, as well as the Finnish co-investment fund Innovestor, have joined our initiative. Thanks to this, the company was able to secure more capital and get off to a stronger start,” added Goroško.
Cells need a scaffold
Growing human tissue in the lab takes more than culturing cells. Cells need a supporting structure around them, where they can attach, grow and organise into tissue. In the body, this job is done by the extracellular matrix; in the lab, by a gel.
Many of the gels in use today are animal-derived, for example extracted from mouse tumour tissue. Their composition varies from batch to batch, and they are difficult to get approved for use in humans. This is one of the biggest bottlenecks in tissue engineering.
LifeGlue’s Glue4Life materials are made from hyaluronic acid, which many people know from skincare products. The body uses it as a building block of skin and joints, among other things. The materials contain no animal-derived components, their composition is precisely defined, and they degrade naturally in the body. Thanks to a patented formulation, the gel forms without UV light or light-activated chemicals, which spares sensitive human stem cells.
One raw material, many tissues
LifeGlue does not develop tissue grafts or therapies itself. It supplies the raw material to those who do. This is a deliberate choice: the same Glue4Life platform can be adapted to produce very different soft tissues, from brain and nerve to liver, fat and the cornea of the eye.
“Tissue engineering is not about solving one problem but hundreds. If we had picked one tissue and developed our own therapy, we would be advancing a single idea. As a raw material supplier, we can be part of every one of them. The more developers succeed around the world, the more patients will ultimately benefit,” says Laura Kuittinen, CEO of LifeGlue Technologies.
For developers, it matters that the same material can be used throughout the journey: from the first lab experiments to industrial manufacturing and, eventually, patient care. Switching materials mid-development can mean years of additional work.
15 customers on three continents
Glue4Life materials are already used by 15 paying customers in Europe, the United States and Australia, even though LifeGlue only began commercial operations in December 2024. The customers are companies and research groups that grow tissue in the lab, such as brain, liver, nerve and fat tissue. For many of them, the long-term goal is a graft that can repair damaged tissue. At Tampere University, the material has been used to produce corneal tissue, with the aim of one day replacing donor corneal grafts, which are in short supply worldwide.
With the funding, LifeGlue will begin building production that meets pharmaceutical GMP (Good Manufacturing Practice) quality standards. This is a prerequisite for customers to take tissues made with the material into clinical trials and, ultimately, to patients. The company will also grow its international sales and build long-term partnerships with its customers.
The first patient treatments are still years away, as lab-grown tissues and grafts require extensive clinical trials.
From research to company
Development of the Glue4Life technology began in 2018 in Professor Heli Skottman’s research group at Tampere University. Its performance has been demonstrated in peer-reviewed scientific publications. The company holds a patent in the United States, with patent applications pending in other key markets.
About LifeGlue
LifeGlue Technologies, based in Tampere, Finland, develops and manufactures hyaluronic acid-based Glue4Life biomaterials for growing human tissue in the lab. The materials contain no animal-derived components. The company supplies them as a raw material to developers of tissue engineering, cell therapies and 3D bioprinting in Europe, the United States and Australia. LifeGlue was spun out of Tampere University and began commercial operations in December 2024. Its recognitions include winning the sTARTUp Day 2026 pitch competition in Tartu, Arctic15’s 100 Innovations Shaping the Future competition and the NORDEEP 2026 Global Deep Tech award.

